A prodrug (doxorubicin-P18) based on neuropeptide Y analog showing cancer microenvironment responsiveness has been developed to fight triple-negative BC cells: this prodrug exerted a higher suppression of tumor growth and metastasis than the administration of free doxorubicin [210]. The gene discussed is NPY; the disease is breast cancer.